Tue, Dec 01, 2020 @ 02:51 GMT
Home COVID-19 Update: More Positive Vaccine News from Pfizer and Moderna

COVID-19 Update: More Positive Vaccine News from Pfizer and Moderna

Overall – current thinking

While the situation in Europe is still serious, we see more rays of light. Many countries now see a turnaround in new infections and this week France joined the club with a big decline in new cases. In the Nordics, Finland has also achieved stabilisation, while new cases keep rising in Norway and Sweden. Italy is finally showing signs of stabilisation but the level of new cases is still high and pressure on hospitals significant. Looking ahead, we believe restrictions will be with us for a long time. Especially as we head into the winter and the Christmas season, there is a clear risk that the virus will spread faster again. The virus survives better in cold temperatures, we are more indoors and we see more people around Christmas. Hence, the need for vigilance will be with us through the whole winter.

In the US, the situation is worsening fast with an acceleration in new infections and record-high hospitalisation rates. As we have argued for some time, more and more states are tightening restrictions and more are still likely to follow suit. The economy will thus face renewed headwinds over the coming months.

We have received plenty of good vaccine news over the last couple of weeks. Both Pfizer and Moderna have showed an efficacy around 95% and both will soon seek an Emergency Use Authorisation. AstraZeneca is expected to release its late stage phase 3 results very soon and Johnson & Johnson is expected to have results ready no later than February. While a vaccine will not alter the fact that it will be a long winter with many restrictions, a vaccine rolled out early next year should limit the need for restrictions next autumn.

Full report in PDF.

Danske Bankhttp://www.danskebank.com/danskeresearch
This publication has been prepared by Danske Markets for information purposes only. It is not an offer or solicitation of any offer to purchase or sell any financial instrument. Whilst reasonable care has been taken to ensure that its contents are not untrue or misleading, no representation is made as to its accuracy or completeness and no liability is accepted for any loss arising from reliance on it. Danske Bank, its affiliates or staff, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives), of any issuer mentioned herein. Danske Markets´ research analysts are not permitted to invest in securities under coverage in their research sector. This publication is not intended for private customers in the UK or any person in the US. Danske Markets is a division of Danske Bank A/S, which is regulated by FSA for the conduct of designated investment business in the UK and is a member of the London Stock Exchange. Copyright (©) Danske Bank A/S. All rights reserved. This publication is protected by copyright and may not be reproduced in whole or in part without permission.

Featured Analysis

Learn Forex Trading